Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:C07D

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/102857METHODS FOR MANAGEMENT OF WEIGHT
WO 28.05.2020
Int.Class A61K 31/5517
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
551having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
55131,4-Benzodiazepines, e.g. diazepam
5517condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
Appl.No PCT/AU2019/051284 Applicant THE UNIVERSITY OF SYDNEY Inventor MCGREGOR, Iain Stewart
Disclosed herein are methods for causing weight loss, for managing weight, and for suppressing an appetite for food in a subject, and methods for reducing the consumption of food by a subject by administering the compounds, or pharmaceutically acceptable salts or prodrugs thereof, of the invention.
2.WO/2020/103817TGF-βR1 INHIBITOR AND USE THEREOF
WO 28.05.2020
Int.Class C07D 401/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
Appl.No PCT/CN2019/119413 Applicant NANJING SANHOME PHARMACEUTICAL CO., LTD. Inventor WANG, Yong
The present invention belongs to the field of medicinal chemistry, and relates to a class of compounds as a TGF-βR1 inhibitor and the use thereof. Specifically, provided in the present invention are a compound shown in formula I, or an isomer, a pharmaceutically acceptable salt, a solvate, a crystal or a prodrug thereof, a preparation method therefor and a pharmaceutical composition containing these compounds, and the use of these compounds or compositions for treating and/or preventing TGF-βR1-related diseases, such as cancers, tissue proliferative diseases, fibrosis and inflammatory diseases. The compounds of the present invention exhibit significant inhibitory activity on TGF-βR1 kinases, and have very strong potential to be therapeutic agents for TGF-βR1-related diseases. (I)
3.WO/2020/103897HETEROCYCLIC FUSED PYRIMIDINE DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION THEREOF
WO 28.05.2020
Int.Class A61K 31/7064
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
Appl.No PCT/CN2019/119899 Applicant SHANGHAI DE NOVO PHARMATECH CO., LTD. Inventor ZHAO, Zhiming
A heterocyclic fused pyrimidine derivative, a pharmaceutical composition thereof, and an application thereof. A heterocyclic fused pyrimidine derivative (I), and an isomer, prodrug, stable isotope derivative, or pharmaceutically acceptable salts thereof have the following structure. The heterocyclic fused pyrimidine derivative can inhibit the ATR level well both in vivo and in vitro. Furthermore, the heterocyclic fused pyrimidine derivative can be also used for effectively treating diseases caused by the abnormal ATR level such as cancer.
4.WO/2020/104267α2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA
WO 28.05.2020
Int.Class C07D 401/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
Appl.No PCT/EP2019/081134 Applicant BAYER AKTIENGESELLSCHAFT Inventor DELBECK, Martina
The present invention relates to α2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular substituted bipiperidinyl derivatives of formula (I) for the use in a method for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring. Formula (I) in which Y is a group (A) or (B).
5.WO/2020/104657NLRP3 INHIBITORS
WO 28.05.2020
Int.Class A61P 3/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
Appl.No PCT/EP2019/082231 Applicant INFLAZOME LIMITED Inventor COOPER, Matthew
The present application relates to compounds with NLRP3inhibitory activity and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present application further relates to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3inhibition.
6.WO/2020/106707APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
WO 28.05.2020
Int.Class A61K 31/4985
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
Appl.No PCT/US2019/062197 Applicant ENANTA PHARMACEUTICALS, INC. Inventor GRANGER, Brett
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-l), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-l related disease. The invention also relates to methods of treating an ASK-l related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-l associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
7.WO/2020/106717COMPOUNDS FOR PHOTODYNAMIC THERAPY AND RELATED USES
WO 28.05.2020
Int.Class C07D 213/69
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
213Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
02having three double bonds between ring members or between ring members and non-ring members
04having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
60with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
62Oxygen or sulfur atoms
69Two or more oxygen atoms
Appl.No PCT/US2019/062210 Applicant GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. Inventor HENARY, Maged
Disclosed herein are symmetrical and unsymmetrical carbocyanine dyes. Irradiation of the dyes generates reactive species which contribute to DNA damage. The dyes are useful for the treatment of various cancers and cell growth disorders.
8.WO/2020/106927GABOXADOL FOR REDUCING RISK OF SUICIDE AND RAPID RELIEF OF DEPRESSION
WO 28.05.2020
Int.Class A61K 31/437
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
437the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
Appl.No PCT/US2019/062554 Applicant CERTEGO THERAPEUTICS Inventor OSTEN, Pavel
Methods and compositions are disclosed for rapidly reducing the risk of suicide in patients suffering from acute suieidality and rapidly relieving mood symptoms in major depression and treatment-resistant depression using a novel therapeutic regimen comprising a single or intermittent administration of a high dose of gaboxadol, or a pharmaceutically acceptable salt thereof, to the subject in need thereof.
9.WO/2020/103856MMPL3 INHIBITORS, COMPOSITIONS AND USES THEREOF
WO 28.05.2020
Int.Class C07D 231/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
231Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
02not condensed with other rings
10having two or three double bonds between ring members or between ring members and non-ring members
14with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Appl.No PCT/CN2019/119668 Applicant SHANGHAITECH UNIVERSITY Inventor RAO, Zihe
Disclosed are inhibitors of mycobacterial membrane protein MmpL3, compositions comprising the inhibitors, and methods of preparation and use thereof.
10.WO/2020/103896PYRROLO[2,3-B]PYRIDINES AS HPK1 INHIBITOR AND USES THEREOF
WO 28.05.2020
Int.Class C07D 471/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
Appl.No PCT/CN2019/119896 Applicant BEIGENE, LTD. Inventor LI, Jing
Disclosed herein is a compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.